Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.Even the biggest and the best companies can undergo periods when things just don't go their way. One especially comes to mind for me. Here's an S&P 500 dividend stock down 56% to buy and hold forever.The main culprit behind the PfizzleI won't prolong the suspense. The stock I'm talking about is Pfizer (PFE 0.11%). And it has admittedly been a lose ...

Given its key role in the fight against COVID-19, the fact that Pfizer (PFE 0.11%) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and its treatment (Paxlovid) soared during the pandemic's height. With the coronavirus contagion abating in the meantime, though, last year's sales fell 41%. Income fell more than 70% year over year. Yikes.However, the stock's sellers have arguably overshot their target. Pfizer stock is not only now well undervalued ...

2024年初，全球医药行业的领军企业陆续发布了2023年财报。亿欧大健康紧密关注的15家跨国医药公司（MNC）中，强生以全球852亿美元的总营收脱颖而出，罗氏和默沙东紧随其后。而去年还以超过千亿美元的营收占据行业头名的辉瑞，今年未能保持*地位，遗憾地退出了前三的行列。 从增速来看，强生、赛诺菲、阿斯利康、诺华、礼来、诺和诺德、安进等11家公司均实现了营收的正增长。相比之下，辉瑞、艾伯维、BMS、吉利德等公司的增长速度有所放缓。 这一轮医药公司的财报发布不仅为全球医药市场带来了新的竞争格局和看点，也揭示了医药行业的未来发展趋势。在这场激烈的竞争中，哪些公司能够抓住机遇，持续创新布局，将成为业界关注的焦点。 01  全球制药TOP3洗牌，辉瑞跌出前三 强生在完成消费者保健业务的分拆后，继续延续2023上半年*的强劲势头，以全年852亿美元营收占据榜首，其制药业务共实现营收547.59亿美元，同比增长4.2%。这一增长主要得益于自身免疫、肿瘤、神经科学、感染、肺动脉高压、心血管及代谢等领域的强劲表现。其中，自免与肿瘤学业务分别贡献了180.52亿和176.61亿美元营收，增长率分别达到了6.6%和10.5%，是拉 ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease). Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more sym ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company’s next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3 – 6 March 2024. Kimberly Smith, M.D ...

New York, United States, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Increasing Prevalence of Cancer Cachexia to Drive the Global Cancer Cachexia Market According to the International Agency for Research on Cancer-Globocan 2020 report, there will be 19,292,789 new cancer cases and 9,958,133 cancer-related deaths globally in 2020. Globally, it was estimated that there were 50,550,287 occurrences of cancer over five years. The global incidence of new cancer cases is projected to reach 28,887,940 by 2040. Moreover, acco ...

With Pfizer (PFE -2.09%) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last week, Guggenheim analyst Vamil Divan said he believes Pfizer is worth $36 per share. That would represent a gain of about 30% from Friday's closing price.Pfizer's cash generated from operations soared during the COVID-19 pandemic, and its share price soared along with it. But Pfizer stock has dropped by more than ...

JuSun Introduction I've written a lot about how overvalued dividend stocks have been during the past 4 years. Other than a brief period in March 2020, when a few good higher-yield stocks were trading at attractive valuations, the massive influx of Baby Boomers going into retirement combined with a decade of low bond yields pushed many investors into stocks who were seeking income from dividends. While most dividend stocks are still in a bubble, there is one that has been left for dead by investors: Pfiz ...

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 13-5315170 (State or other jurisdiction of incorporation ...